Hyperkalemia and its Association With Mortality, Cardiovascular Events, Hospitalizations, and Intensive Care Unit Admissions in a Population-Based Retrospective Cohort

被引:41
作者
Hougen, Ingrid [1 ]
Leon, Silvia J. [2 ,3 ]
Whitlock, Reid [2 ]
Rigatto, Claudio [1 ,2 ,3 ]
Komenda, Paul [1 ,2 ,3 ]
Bohm, Clara [1 ,2 ,3 ]
Tangri, Navdeep [1 ,2 ,3 ]
机构
[1] Univ Manitoba, Max Rady Coll Med, Dept Internal Med, Winnipeg, MB, Canada
[2] Seven Oaks Gen Hosp, Chron Dis Innovat Ctr, 2LB19-2300 McPhillips St, Winnipeg, MB R2V 3M3, Canada
[3] Univ Manitoba, Max Rady Coll Med, Dept Community Hlth Sci, Winnipeg, MB, Canada
关键词
diabetes; hyperkalemia; kidney disease; mortality; population; SODIUM ZIRCONIUM CYCLOSILICATE; CHRONIC KIDNEY-DISEASE; SERUM POTASSIUM; HEART-FAILURE; PATIROMER; HYPOKALEMIA; ZS-9;
D O I
10.1016/j.ekir.2021.02.038
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Hyperkalemia is a common, potentially life-threatening condition in patients with chronic kidney disease (CKD). We studied the association between hyperkalemia and mortality, cardiovascular events, hospitalizations, and intensive care unit (ICU) admissions. Methods: We performed a retrospective cohort study using administrative databases in Manitoba, Canada. All adults (>= 18 years of age) with potassium tests between January 2007 and December 2016 were included, with follow-up until March 31, 2017. Propensity score matching was performed among patients with de novo hyperkalemia (serum potassium >= 5.0 mmol/l) and patients who were nonhyperkalemic. The association between hyperkalemia and normokalemia and mortality was assessed using multivariate Cox proportional hazards regression models, adjusting for patient characteristics in a 1:1 propensity score- matched sample. Secondary outcomes included cardiovascular events, hospitalizations, and ICU admissions. A sensitivity analysis was performed with hyperkalemia defined as serum potassium >= 5.5 mmol/l. Results: Of 93,667 patients with de novo hyperkalemia, 36% had diabetes mellitus (DM), 28% had CKD, and 21% had heart failure (HF). In the propensity score-matched sample of 177,082 individuals, hyperkalemia was associated with an increased risk for all-cause mortality (hazard ratio [HR] 1.15 [95% confidence interval {CI} 1.13-1.18], P < 0.001), cardiovascular events (HR 1.20 [95% CI 1.14-1.26], P < 0.001), short-term mortality (odds ratio [OR] 1.29 [95% CI 1.24-1.34], P < 0.001), hospitalizations (OR 1.71 [95% CI 1.68-1.74]), and ICU admissions (OR 3.48 [95% CI 3.34-3.62], P < 0.001). Findings were unchanged when a threshold of serum potassium >= 5.5 mmol/l was used. Conclusion: Hyperkalemia was an independent risk factor for all-cause mortality, cardiovascular events, hospitalizations, and ICU admissions. This finding expands our understanding of important clinical outcomes associated with hyperkalemia.
引用
收藏
页码:1309 / 1316
页数:8
相关论文
共 30 条
[1]   Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial [J].
Agarwal, Rajiv ;
Rossignol, Patrick ;
Romero, Alain ;
Garza, Dahlia ;
Mayo, Martha R. ;
Warren, Suzette ;
Ma, Jia ;
White, William B. ;
Williams, Bryan .
LANCET, 2019, 394 (10208) :1540-1550
[2]   Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial [J].
Anker, Stefan D. ;
Kosiborod, Mikhail ;
Zannad, Faiez ;
Pina, Ileana L. ;
McCullough, Peter A. ;
Filippatos, Gerasimos ;
van der Meer, Peter ;
Ponikowski, Piotr ;
Rasmussen, Henrik S. ;
Lavin, Philip T. ;
Singh, Bhupinder ;
Yang, Alex ;
Deedwania, Prakash .
EUROPEAN JOURNAL OF HEART FAILURE, 2015, 17 (10) :1050-1056
[3]   A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient [J].
Ash, Stephen R. ;
Singh, Bhupinder ;
Lavin, Philip T. ;
Stavros, Fiona ;
Rasmussen, Henrik S. .
KIDNEY INTERNATIONAL, 2015, 88 (02) :404-411
[4]   Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease The AMETHYST-DN Randomized Clinical Trial [J].
Bakris, George L. ;
Pitt, Bertram ;
Weir, Matthew R. ;
Freeman, Mason W. ;
Mayo, Martha R. ;
Garza, Dahlia ;
Stasiv, Yuri ;
Zawadzki, Rezi ;
Berman, Lance ;
Bushinsky, David A. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (02) :151-161
[5]   Association of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and/or Diabetes [J].
Collins, Allan J. ;
Pitt, Bertram ;
Reaven, Nancy ;
Funk, Susan ;
McGaughey, Karen ;
Wilson, Daniel ;
Bushinsky, David A. .
AMERICAN JOURNAL OF NEPHROLOGY, 2017, 46 (03) :213-221
[6]   Efficacy and Safety of Patiromer in Hyperkalemia: A Systematic Review and Meta-Analysis [J].
Das, Saibal ;
Dey, Jayanta Kumar ;
Sen, Sumalya ;
Mukherjee, Rishav .
JOURNAL OF PHARMACY PRACTICE, 2018, 31 (01) :6-17
[7]   The Frequency of Hyperkalemia and Its Significance in Chronic Kidney Disease [J].
Einhorn, Lisa M. ;
Zhan, Min ;
Hsu, Van Doren ;
Walker, Lori D. ;
Moen, Maureen F. ;
Seliger, Stephen L. ;
Weir, Matthew R. ;
Fink, Jeffrey C. .
ARCHIVES OF INTERNAL MEDICINE, 2009, 169 (12) :1156-1162
[8]   Potassium levels and risk of in-hospital arrhythmias and mortality in patients admitted with suspected acute coronary syndrome [J].
Faxen, Jonas ;
Xu, Hong ;
Evans, Marie ;
Jernberg, Tomas ;
Szummer, Karolina ;
Carrero, Juan-Jesus .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2019, 274 :52-58
[9]  
Fitch K, 2017, AM HEALTH DRUG BENEF, V10, P202
[10]   Hyperkalemia and Hypokalemia in CKD: Prevalence, Risk Factors, and Clinical Outcomes [J].
Gilligan, Sarah ;
Raphael, Kalani L. .
ADVANCES IN CHRONIC KIDNEY DISEASE, 2017, 24 (05) :315-318